Physician profile
Joseph E Temming
NPI 1407851215
$1,685.55
in general payments reported to CMS, 2019-2025
14 companies · $66.69 in 2025
The $66.69 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.30 · 2020: $22.36 · 2021: $225 · 2022: $674 · 2023: $398 · 2024: $285 · 2025: $66.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $650 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $650.28 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $438.23 | 2020-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $365.02 | 2022-2024 | |
| Amgen INC. | $185.92 | 2021-2025 | Enbrel, Tavneos, Otezla |
| Janssen Biotech, INC. | $174.98 | 2022-2024 | Tremfya |
| Ucb, INC. | $155.97 | 2022-2023 | Cimzia |
| Horizon Therapeutics Plc | $139.57 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $54.86 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $40.84 | 2022 | |
| Pfizer INC. | $32.76 | 2022-2025 | |
| Ultragenyx Pharmaceutical INC. | $24.87 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $20.38 | 2022 | |
| Ani Pharmaceuticals, INC. | $19.67 | 2022 | |
| Fresenius Kabi USA, LLC | $18.18 | 2025 | |
| Depuy Synthes Sales INC. | $14.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Temming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.